The European Commission has granted marketing authorisation for Ranluspec, a biosimilar for the treatment of neovascular (wet) age-related macular degeneration (nAMD), visual impairment due to diabetic macular oedema, proliferative diabetic retinopathy, visual impairment due to macular oedema secondary to retinal vein occlusion and visual impairment due to choroidal neovascularisation.1 Ranluspec has equivalent efficacy and comparable safety to its reference medicine, Lucentis.2
Ranluspec was developed, manufactured and registered by Lupin. Sandoz holds exclusive commercialisation rights for Ranluspec across the European Union, excluding Germany, and semi-exclusive rights in France.
Ranluspec has equivalent efficacy and comparable safety to its reference medicine, Lucentis
References
1 European Medicines Agency (EMA). Ranluspec (ranibizumab): Product Details. Available from: ema.europa.eu/en/medicines/human/EPAR/ranluspec [Last accessed: Feb 2026]
2 European Medicines Agency (EMA). Lucentis (ranibizumab): Prescribing Information. Available from: ema.europa.eu/en/medicines/human/EPAR/lucentis [Last accessed: Feb 2026]
